Frontiers in Oncology (Jan 2022)
Interaction of ncRNA and Epigenetic Modifications in Gastric Cancer: Focus on Histone Modification
- Qingfan Yang,
- Qingfan Yang,
- Yu Chen,
- Yu Chen,
- Yu Chen,
- Rui Guo,
- Yalan Dai,
- Yalan Dai,
- Liyao Tang,
- Liyao Tang,
- Yueshui Zhao,
- Yueshui Zhao,
- Yueshui Zhao,
- Xu Wu,
- Xu Wu,
- Xu Wu,
- Mingxing Li,
- Mingxing Li,
- Mingxing Li,
- Fukuan Du,
- Fukuan Du,
- Fukuan Du,
- Jing Shen,
- Jing Shen,
- Jing Shen,
- Tao Yi,
- Zhangang Xiao,
- Zhangang Xiao,
- Zhangang Xiao,
- Qinglian Wen,
- Qinglian Wen
Affiliations
- Qingfan Yang
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China
- Qingfan Yang
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yu Chen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yu Chen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yu Chen
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Rui Guo
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China
- Yalan Dai
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China
- Yalan Dai
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Liyao Tang
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Liyao Tang
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Yueshui Zhao
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yueshui Zhao
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yueshui Zhao
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Xu Wu
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Xu Wu
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xu Wu
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Mingxing Li
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Mingxing Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Mingxing Li
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Fukuan Du
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Fukuan Du
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Fukuan Du
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Jing Shen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Jing Shen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Jing Shen
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Tao Yi
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong SAR, China
- Zhangang Xiao
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Zhangang Xiao
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Zhangang Xiao
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Qinglian Wen
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China
- Qinglian Wen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.822745
- Journal volume & issue
-
Vol. 11
Abstract
Gastric cancer has developed as a very common gastrointestinal tumors, with recent effective advancements in the diagnosis and treatment of early gastric cancer. However, the prognosis for gastric cancer remains poor. As a result, there is in sore need of better understanding the mechanisms of gastric cancer development and progression to improve existing diagnostic and treatment options. In recent years, epigenetics has been recognized as an important contributor on tumor progression. Epigenetic changes in cancer include chromatin remodeling, DNA methylation and histone modifications. An increasing number of studies demonstrated that noncoding RNAs (ncRNAs) are associated with epigenetic changes in gastric cancer. Herein, we describe the molecular interactions of histone modifications and ncRNAs in epigenetics. We focus on ncRNA-mediated histone modifications of gene expression associated with tumorigenesis and progression in gastric cancer. This molecular mechanism will contribute to our deeper understanding of gastric carcinogenesis and progression, thus providing innovations in gastric cancer diagnosis and treatment strategies.
Keywords
